Literature DB >> 7625188

The Cantabria first episode schizophrenia study: a summary of general findings.

J L Vázquez-Barquero1, M J Cuesta Nuñez, M de la Varga, S Herrera Castanedo, L Gaite, A Arenal.   

Abstract

This article describes the general findings of the initial cross-sectional stage of a prospective follow-up study of all first episodes of schizophrenia that occurred in the Autonomous Community of Cantabria over a 2-year period and that established contact with any mental health service. The project comprises: i) a 2-year cross-sectional stage, in which the sample was gathered and studied with structured psychiatric instruments such as the Present State Examination and the Scales for the Assessment of Negative and Positive Symptoms (SANS and SAPS), and; ii) a continuous follow-up. We detected, in the risk age ranged of 15-54 years, an incidence of 1.9 per 10,000 inhabitants per year for schizophrenia and of 1.3 per 10,000 inhabitants per year for the S+ CATEGO diagnosis, without any significant gender difference of morbidity. The mean age for the total schizophrenic population was 26 years, being significantly higher in women than in men. In contrast with what happens with marital status, type of household or urban/rural way of life, there was no gender difference in relation to the other sociodemographic variables. The way in which nosological and clinical variables are associated with first episodes of schizophrenia was also examined in this study. We found that 75% of patients reached a maximum CATEGO-ID level, 71% received a S+ CATEGO diagnosis, 59% presented first-rank symptoms of schizophrenia and that the percentage of a schizophrenic negative syndrome, as identified by the SANS and SAPS, was very low.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7625188     DOI: 10.1111/j.1600-0447.1995.tb09759.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  6 in total

Review 1.  First rank symptoms for schizophrenia.

Authors:  Karla Soares-Weiser; Nicola Maayan; Hanna Bergman; Clare Davenport; Amanda J Kirkham; Sarah Grabowski; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2015-01-25

2.  Trends on schizophrenia admissions during the deinstitutionalisation process in Spain (1980-2004).

Authors:  Zuleika Saz-Parkinson; A Medel; P Cediel-García; J Castellote; C Bouza; J M Amate
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-10-24       Impact factor: 4.328

3.  Assessment of premorbid function in first-episode schizophrenia: modifications to the Premorbid Adjustment Scale.

Authors:  Sarah van Mastrigt; Jean Addington
Journal:  J Psychiatry Neurosci       Date:  2002-03       Impact factor: 6.186

4.  Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain.

Authors:  Javier Quintero; Itziar Oyagüez; Beatriz González; Ignacio Cuervo-Arango; Ignacio García; Miguel Angel Casado
Journal:  Clin Drug Investig       Date:  2016-06       Impact factor: 2.859

5.  Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses.

Authors:  Antonio J García-Ruiz; Lucía Pérez-Costillas; Ana C Montesinos; Javier Alcalde; Itziar Oyagüez; Miguel A Casado
Journal:  Health Econ Rev       Date:  2012-04-10

Review 6.  A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology.

Authors:  John McGrath; Sukanta Saha; Joy Welham; Ossama El Saadi; Clare MacCauley; David Chant
Journal:  BMC Med       Date:  2004-04-28       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.